

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Purapharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 25 June 2026, and Prof. Tsui Lap Chee (“**Prof. Tsui**”) resigned as an independent non-executive Director of the Company and ceased to be a member of each of the audit committee, remuneration committee and nomination committee of the Board.

Prof. Tsui confirmed that as at the date of this announcement, (i) he does not have any claim against the Company in respect of his resignation; (ii) he does not have any disagreement with the Board; and (iii) there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Prof. Tsui, who was appointed as an independent non-executive Director on 12 June 2015, has served as an independent non-executive Director for more than nine years and was a long-serving independent non-executive Director as defined under the amendments to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), which took effect from 1 July 2025. Prof. Tsui took into account of the new requirement under the Listing Rules on long-serving independent non-executive Directors that, in his view on maintaining good corporate governance, Prof. Tsui tendered his resignation as an independent non-executive Director to support the renewal and succession of the Board.

The Board would like to take the opportunity to express its gratitude to Prof. Tsui for his contribution to the Company during his term of office.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 25 June 2026

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Directors are Mr. Leung Stephen Kwok Keung and Mr. Dong Zimeng; and the independent non-executive Directors are Dr. Hung Ting On, John, Dr. Leung Lim Kin, Simon, Mr. Lee Stephen and Prof. Ng Wang Wai Charles.